Will The STARS Add Shine To VectivBio?

Switzerland-based VectivBio is a global, clinical-stage biotechnology company developing innovative treatments for severe rare conditions with significant unmet medical need. The lead drug candidate is Apraglutide, a next-generation GLP-2 analog, which according to the company represents a potential "pipeline in a product" opportunity.

from RTT - Top Story https://ift.tt/0HIduD6
via IFTTT